Optimized immunosuppression strategy in MHC-matched allogeneic iPS cell-based transplantation

Abstract

In transplantation medicine using iPS cells, it is planned to use off-the-shelf iPS cells derived from allogeneic iPS cells for rapid and low-cost utilization of clinical-grade cells. To reduce the possibility of rejection, it is designed to use HLA-homozygous iPS cells for the off-the-shelf product, and several lines have been established for future HLA-matched transplants. This article describes our efforts to control rejection in HLA-matched allogeneic iPS cell-based transplantation, focusing on establishing immunosuppression protocols.